Po‐Lan Su

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer”.

Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer

Investigational New Drugs(2025)10.1007/s10637-025-01591-y

N/A

0.165DataRank · unranked

2 citations

Ruohan Wu, Lai Wei, Mikhail M. Dikov, Shankar Suman, Po‐Lan Su +17 more

Deep-learning-enabled multi-omics analyses for prediction of future metastasis in cancer

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.16.654579

N/A

0DataRank · unranked

0 citations

Maoteng Duan, Po‐Lan Su, Jianying Li, Jordan E. Krull, Jiacheng Jin +15 more

Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non‐Small‐Cell Lung Cancer Treated With Front‐Line Immunotherapy‐Based Therapies

Cancer Medicine(2025)10.1002/cam4.71058

N/A

0DataRank · unranked

0 citations

Po‐Lan Su, Songzhu Zhao, Grace Cheng, Nicholas Jones, Kenneth Chian +26 more